A Phase 3 interventional study of Mechanical cervical ripening and Pharmacological cervical ripening in Prolonged Pregnancy, sponsored by University Hospital, Tours. Completed at 14 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by University Hospital, Tours · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A pregnancy is considered ''prolonged'' from 41 weeks of gestation. Prolonged Pregnancies (PP) are associated with increased maternal morbidity: emergency caesarean, 3rd and 4th degree perineal lesions and postpartum haemorrhage. Foetuses are at increased risk of oligohydramnios, meconium-staining and Fetal Heart Rate (FHR) anomalies. Around 15% of all pregnancies are prolonged.
A Cochrane review on induction of labour showed that a policy of labour induction at or beyond 41 weeks was associated with significantly fewer perinatal deaths. Thus the French College of Obstetricians and Gynaecologists stated, "induction of labour can be proposed to patients between 41+0 and 41+6 weeks of gestation". In cases where labour is induced and cervix is unfavourable, cervical ripening is advised. Methods of cervical ripening include pharmacological (prostaglandins) and mechanical (Foley catheter or trans-cervical double balloon) methods. Those two methods were compared in the PROBAAT trial among women with term pregnancies (beyond 37+0). The rates of caesarean section with these two strategies were identical, however uterine hyper stimulation with FHR anomalies occurred less when cervical ripening was mechanical.
Considering pharmacological cervical ripening is associated with more uterine hyper stimulation and more FHR anomalies, it may not be the most appropriate in cases of fragile foetuses that include cases of prolonged pregnancies. Considering prolonged pregnancies are associated with a risk of FHR anomalies and that cervical ripening with a pharmacological method is another factor which increases this risk: women with prolonged pregnancies could benefit from a more "gentle" cervical ripening.
At present, no particular method is recommended in cases of cervical ripening and prolonged pregnancies. We hypothesise that, in cases of prolonged pregnancies, mechanical cervical ripening, with less uterine hyperstimulation and fewer FHR anomalies, could be more appropriate and could reduce the rate of caesarean section for suspicion of fetal distress.
30 studies on the registry are indexed under Pregnancy, Prolonged; 3 are open to participants now.
This study's enrollment of 1,224 is above the median of 128 across 24 interventional studies indexed under Pregnancy, Prolonged.
Browse Pregnancy, Prolonged studies →University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe preeclampsia defined as the presence of preeclampsia with at least one of the following items :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
mechanical cervical ripening with a Cook® Cervical Ripening Balloon
Device: Mechanical cervical ripening
pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
Drug: Pharmacological cervical ripening
The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon. It will be used in accordance with user manual
The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2). It will be used in accordance with Summary of Product Characteristics
Caesarean section rate for non-reassuring fetal status.
Indication of the caesarean section will be settled by an adjudication committee at the end of the study
Time frame: Up to 2 days after cervical ripening
Time between cervical ripening and delivery in hours
Evaluation of time between cervical ripening and delivery in hours
Time frame: Up to 2 days after cervical ripening
Delivery rate after 12 and 24 hours of cervical ripening
Evaluation of delivery rate after 12 and 24 hours of cervical ripening
Time frame: up to 2 days after cervical ripening
Induction with oxytocin
yes/no
Time frame: up to 2 days after cervical ripening
Total dose of oxytocin required for induction of labour
evaluation of total dose of oxytocin required for induction of labour
Time frame: up to 2 days after cervical ripening
Uterine hyper stimulation defined as more than 6 contractions by 10 minutes over a 30 minutes period
uterine hyperstimulation
Time frame: up to 2 days after cervical ripening
Requirement for tocolysis during cervical ripening or during labour
requirement for tocolysis
Time frame: up to 2 days after cervical ripening
Suspicious or pathological fetal heart rate
FIGO classification
Time frame: up to 2 days after cervical ripening
Uterine rupture
yes/no
Time frame: up to 2 days after cervical ripening
Use of analgesics during labour
yes/no
Time frame: up to 2 days after cervical ripening
Use of antibiotics during labour
yes/no
Time frame: up to 2 days after cervical ripening
Indication for caesarean delivery other than non-reassuring FHR
(failure to progress in first or second stage of labour or maternal indication)
Time frame: up to 2 days after cervical ripening
Type of vaginal delivery
spontaneous or instrumental, indication for instrumental delivery
Time frame: up to 2 days after cervical ripening
Maternal intra partum infection
Suspicion of maternal intra partum infection
Time frame: up to 2 days after cervical ripening
Maternal post partum infection
Suspicion of post partum infection
Time frame: up to 2 days after cervical ripening
Maternal post partum haemorrhage
Post partum haemorrhage defined as estimated blood loss \> 500 cc
Time frame: up to 2 days after cervical ripening
Maternal blood transfusion
Blood transfusion
Time frame: up to 2 days after cervical ripening
Neonatal apgar score
Apgar score at 1, 3, 5 and 10 minutes
Time frame: at 1, 3, 5 and 10 minutes after delivery
Neonatal arterial ph
Arterial pH at delivery
Time frame: at delivery
Intensive care unit for newborn
Admission in an intensive care unit
Time frame: up to 5 days after cervical ripening
Neonatal respiratory insufficiency
Respiratory insufficiency with necessity of any respiratory support
Time frame: up to 5 days after cervical ripening
Birth asphyxia
Birth asphyxia defined as pH\<7, Base Excess \>12 mmol/l and encephalopathy.
Time frame: up to 5 days after cervical ripening
Ran from Jan 2017 to primary completion in Dec 2018, 22 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.